DMD Competition

After researching and investing in ANP I was curious to see what other clinical drugs are being studied to treat DMD and was surprised to find there's actually quite a few in development (nicely summed up in the below link) for the different symptoms/aspects of the disease.

https://www.parentprojectmd.org/duchenne-drug-development-pipeline/

One clinical drug that caught my eye was Edasalonexent developed by Catabasis because just like ATL1102 it is targeting muscle inflammation. It's currently in Phase 3 trials with the FDA with top-line data expected in Q4. Its phase 2 results were fairly positive and so I was surprised to see the company's market cap is only ~$120mil USD. Still multiples more than ANP, but I would've expected it would be higher. That said, I'd be curious to know if anyone here has researched or invested in any of the competition, and how do you account for the wide disparity in valuations between smaller players like Antisense and Catabasis and giants like Sarepta. To me it seems like the price a DMD drug can support varies widely based on what specific aspect of DMD it is treating and perhaps how many other players are developing similar treatments.